DLL4

DLL4 Overview

English NameDelta-like protein 4Approved Drugs0
Drugs in Clinical Trials3Target SynonymDelta-Like Protein 4,Notch Ligand Delta-2,DLL4,Delta4,Delta-Like 4 (Drosophila),Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Notch Ligand DLL4,Delta Like Canonical Notch Ligand 4,Delta 4,Delta Ligand 4,Delta-Like 4 Protein,Drosophila Delta Homolog 4,Delta-Like 4 Homolog
Highest Development StagePhase 3 Clinical
English NameDelta-like protein 4
Target SynonymDelta-Like Protein 4,Notch Ligand Delta-2,DLL4,Delta4,Delta-Like 4 (Drosophila),Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Notch Ligand DLL4,Delta Like Canonical Notch Ligand 4,Delta 4,Delta Ligand 4,Delta-Like 4 Protein,Drosophila Delta Homolog 4,Delta-Like 4 Homolog
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 3 Clinical

DLL4 Background

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

DLL4 Synonyms

DLL4,Delta4

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TovecimigES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001Phase 3 ClinicalAbl Bio IncAmpullary Carcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Rectal Neoplasms; Solid tumours
Details
NavicixizumabOMP-305B83Phase 3 ClinicalOncomed Pharmaceuticals IncColorectal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
DilpacimabABT-165; DVD-Ig ABT-165Phase 1 ClinicalAbbvie IncNeoplasms; Solid tumours
Details

Product Reviews

  • A***r2025-11-15
    0People Like
    I have been using ACRO Biosystems products since 2021, especially DLL4 Fc proteins (DL4-H5259), refer to our published article: https://pubmed.ncbi.nlm.nih.gov/37795096/, where we have used Acro-products and obtained excellent results. I am very satisfied with the consistent quality and reliability of ACRO’s products. Thanks, Ankit Tanwar Staff Scientist AECOM, NY
  • Z***a2022-07-06
    1People Like
    This product was extremely useful for our T cell work. The vial it came in was easy to use (sometimes you'd be surprised how obtuse the packaging of a compound can be by certain companies) and has not lead to any issues with our research in many months. The only obstacle we have ever faced with adherent cells was as a result of our flat bottom plates being too old (and thus the coating wore off). So this product was more stable and consistent than the plates we put them on!
  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland